Building on teh success of mRNA technology demonstrated during the COVID-19 pandemic, researchers are now reporting promising results from a phase 3 clinical trial of a new influenza vaccine. the study, published in the *New england Journal of Medicine*, suggests the mRNA-based vaccine offers comparable or improved efficacy against the flu, tho with a perhaps higher rate of common side effects. This progress arrives as public health officials continue to emphasize the importance of annual flu vaccination, especially for vulnerable populations, with the CDC estimating that seasonal flu has caused between 12,000 and 52,000 deaths annually since 2010 [[3]].
A new influenza vaccine leveraging messenger RNA (mRNA) technology – the same platform that proved pivotal in combating the COVID-19 pandemic – is showing promising results, according to a study published in the New England Journal of Medicine. The development offers a potential pathway to more rapidly adaptable and effective flu protection.
A Phase 3 clinical trial revealed the mRNA vaccine demonstrated comparable, or even superior, efficacy against the flu when compared to traditional vaccines. However, researchers also observed a higher incidence of side effects, such as fever or injection site pain, with the mRNA version.
“The vaccine showed good efficacy against influenza, and I think that’s promising for the future, but there are still several steps before it can be used in practice,” said Dr. Nicholas Brousseau, a specialist in preventive medicine at the National Institute of Public Health of Quebec.
The study involved nearly 18,500 participants between the ages of 18 and 64, with half receiving the modified mRNA vaccine and the other half a placebo.
The modified mRNA vaccine exhibited “statistically superior” efficacy to the placebo and triggered “larger immune responses” against certain influenza strains, while also being “associated with a greater number of adverse events,” the study authors reported.
One key advantage of an mRNA-based flu vaccine, Dr. Brousseau explained, lies in its potential for rapid production. Currently, flu vaccine production begins as early as February, based on recommendations from the World Health Organization (WHO) stemming from analysis of the influenza season ending in the Southern Hemisphere.
This strategy isn’t foolproof, as the influenza virus can mutate between February, when vaccine production starts, and the fall when vaccinations are administered, Dr. Brousseau noted. “The flu is always changing, so the speed of production can be a significant advantage,” he said. “If we can produce the vaccine in a few weeks rather than a few months, we could wait a little longer to choose the exact strains to include in the vaccine.”
Waiting longer, he added, “increases the chances of selecting strains very similar to those circulating in the population in the fall.”
Currently, the biggest challenge, Dr. Brousseau emphasized, is increasing vaccination rates overall. Several flu vaccines are already available, and he stressed the importance of vaccination, particularly for older adults and younger individuals with chronic conditions like diabetes or heart disease.
“Ultimately, the biggest gain we can achieve is reaching more people, regardless of the vaccine,” Dr. Brousseau said.
The study’s findings are based on a Phase 3 clinical trial, the final hurdle a new treatment must clear before seeking regulatory approval. It will likely be several months, or even years, before an mRNA flu vaccine is widely available to the public. Factors such as side effects will be carefully considered before any potential approval.
“This new vaccine isn’t a revolution,” Dr. Brousseau concluded. “There’s still a lot of work to be done to potentially find a vaccine with even higher efficacy, closer to 100%.”
The study, led by Dr. David Fitz-Patrick of the East-West Medical Research Institute in Honolulu, was funded by pharmaceutical company Pfizer, a global leader in mRNA vaccine technology alongside Moderna.
